Gene replacement does not rescue a subset of RBM20 variants causing dilated cardiomyopathy
A bioRxiv preprint reports that damaging variants in the glutamate-rich domain of the cardiac splice regulator RBM20 are not corrected by gene replacement, suggesting they act via a different mechanism from the better-studied RS-domain variants.
Researchers have posted a preprint on bioRxiv examining variant-specific mechanisms in RBM20-associated dilated cardiomyopathy — a highly penetrant and arrhythmogenic inherited heart muscle disease. The cardiac RNA-binding protein RBM20 regulates splicing of multiple genes essential to cardiac function, and pathogenic missense variants in its arginine-serine rich (RS) domain are known to cause disease by forming toxic gain-of-function cytoplasmic granules.
The preprint focuses on a separate set of clinically adjudicated pathogenic variants located in RBM20's glutamate (E)-rich domain. Using a scalable functional screen, the authors find that E-rich domain variants do not form the same cytoplasmic granules and are not rescued by gene replacement strategies — a contrast with RS-domain variants, for which gene replacement has been proposed as a therapeutic approach.
The findings have implications for the classification of RBM20 variants and for the design of precision therapies in genetic cardiomyopathy, where linking specific treatment strategies to variant mechanism is a central challenge. The work is relevant to researchers in inherited cardiac disease and those developing gene therapy strategies. As a preprint, these findings have not yet undergone peer review.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
A gene called RBM20 helps control how the heart muscle works. Faults in this gene can cause a condition called dilated cardiomyopathy, where the heart muscle becomes weakened and enlarged. Scientists have been investigating whether a treatment called gene replacement — essentially adding a correct copy of the gene — could help. This new preprint study suggests that a particular group of RBM20 faults, found in one part of the gene called the E-rich domain, are unlikely to be fixed by gene replacement, because they work differently from the faults that gene replacement was designed to address. This matters because it means doctors and scientists may need different treatment approaches depending on exactly which fault a person carries. This research is at an early stage and has not yet been checked by other independent scientists. This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary sourcePreprint bioRxiv (Cold Spring Harbor Laboratory) · 2026-07-20Damaging RBM20 E-rich domain variants are not rescued by gene replacement